Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAOK1 | Q7L7X3 | 13/20 | 1.00 |
| ▸ | TAOK3 | Q9H2K8 | 9/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31458158 | 1.00 | TAOK1 (1.00) | TAOK1TAOK3ALDH1A1LMNAHPGD | |
| SCHEMBL5653384 | 0.89 | TAOK1 (1.00) | TAOK1TAOK3 | |
| SCHEMBL31458350 | 0.89 | TAOK1 (1.00) | TAOK1TAOK3 | |
| SCHEMBL14422172 | 0.88 | TAOK3 (1.00) | TAOK1TAOK3ALDH1A1LMNAHPGD | |
| SCHEMBL5223796 | 0.88 | TAOK1 (1.00) | TAOK1TAOK3ALDH1A1LMNAHPGD | |
| SCHEMBL31730310 | 0.88 | TAOK3 (1.00) | TAOK1TAOK3ALDH1A1LMNAHPGD | |
| SCHEMBL31458362 | 0.88 | TAOK1 (1.00) | TAOK1TAOK3ALDH1A1LMNAHPGD | |
| SCHEMBL14422171 | 0.85 | TAOK1 (1.00) | TAOK1TAOK3ALDH1A1LMNAHPGD | |
| SCHEMBL31730316 | 0.85 | TAOK1 (1.00) | TAOK1TAOK3ALDH1A1LMNAHPGD | |
| SCHEMBL31458377 | 0.85 | TAOK1 (1.00) | TAOK1TAOK3ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1678121-A4 | TAO KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1678121-A2 | TAO KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005040355-A2 | TAO KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | TAOK1, TAOK3, MAP3K6 | TAOK1 1/4885TAOK3 2/4885ALDH1A1 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.